Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization
Authors' conclusion
Subcutaneous ABL (80 µg/day) results in significant BMD gains by three months in both men and postmenopausal women with osteoporosis at levels associated with decreased fracture risk. Bone formation is increased at 1 month and sustained for 12 months.
Study context
- Population
- Men and postmenopausal women with osteoporosis at high risk for fracture
- Participants
- 149 vs 250
- Comparison
- Men vs Postmenopausal women
- Menn = 149
- Postmenopausal womenn = 250
- Primary endpoint
- Mean percent bone mineral density (BMD) change in the femoral neck, total hip and lumbar spine
- Follow-up
- 3 months
Primary result
As reported in the abstract
Mean % BMD increase at femoral neck, total hip and lumbar spine (entries per group in that order)
Men
1.79
mean · SD 0.35 · %
Men
1.26
mean · SD 0.26 · %
Men
4.14
mean · SD 0.43 · %
Women
1.55
mean · SD 0.28 · %
Women
1.78
mean · SD 0.21 · %
Women
4.42
mean · SD 0.34 · %
Further findings
- Serum P1NP increased over threefold vs baseline at 1 month in women and men
Original publication
Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization. Osteoporos Int. Published 25 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →